Open access

Cognitive Functions in Euthymic Bipolar Patients and Lithium

Written By

Aleksandra Suwalska and Dorota Łojko

Submitted: May 18th, 2012 Published: January 23rd, 2013

DOI: 10.5772/55126

Chapter metrics overview

1,823 Chapter Downloads

View Full Metrics

1. Introduction

Based on Kraepelin’s works we had for many years been distinguishing between manic-depressive illness (bipolar disorder) and dementia praecox (schizophrenia) based on the assumption that bipolar patients tended to experience full remission, whereas the schizophrenic did not. Since the late 1990s, the evidence has been accumulated that the recovery in bipolar disorder is not complete [1]. Persistent psychosocial difficulties and cognitive deficits are common in patients with the bipolar disorder even in euthymic or asymptomatic states [2, 3]. After two decades of scientific work the nature of the cognitive impairments is still the focus of research and debate. The extent and pattern of cognitive impairment in euthymic patients remain uncertain [4]. A meta-analysis of the studies revealed widespread cognitive deficits in patients with schizophrenia and affective disorders in cognitive functioning, speed of information processing, encoding and retrieval, rule discovery, as well as response generation and response inhibition [5]. There is a growing need for clarification regarding the extent and clinical relevance of cognitive impairment in bipolar patients [6].


2. Subjects and methods

2.1. Subjects

Sixty euthymic bipolar patients (25 male, 35 female), aged 26–75 yr (mean±S.D.: 53±10 yr) attending the Outpatient Lithium Clinic at the Department of Psychiatry at the Poznan University of Medical Science were studied. Consensus diagnosis by two psychiatrists was made for each patient, according to DSM-IV criteria (Structured Clinical Interview for DSM-IV Axis I – SCID) [7]. The patients had been treated with lithium carbonate for at least 5 yr. On the day of the study, all patients were euthymic, as defined by a score of <7 on the 17-item Hamilton Depression Rating Scale (HAMD17) [8] and a score of <7 on the Young Mania Rating Scale (YMRS) [9]. Among the patients, 13 were excellent lithium responders, defined as having had no affective episodes on lithium monotherapy for the entire period of lithium administration [10]. Eighty-four healthy controls recruited from the local community were matched by age, gender and education level. The study was approved by the Ethics Committee at the Poznan University of Medical Science. Patients and volunteers gave their written informed consent after hearing a complete description of the study.

2.2. Cognitive assessment- methods

Patients and controls underwent an extensive neuropsychological assessment that included an evaluation of attention, working memory, verbal and visual episodic memory, verbal fluency and executive functions. Neuropsychological testing lasted approximately 2 h. Subjects completed the tests in a fixed order with a break half-way through. The Trail Making Test (TMT) [11], Stroop Colour-Word Interference test [12, 13], verbal fluency tests, as well as selected tests from the Cambridge Automated Neuropsychological Test Battery (CANTAB; CeNeS Ltd, Cambridge, UK) [14-17], were employed.

2.2.1. Cognitive tests: Paper-and-pencil tests

The Trail Making Test (TMT) consists of two parts. TMT requires subjects to connect 25 consecutively numbered circles, (part A) and 25 numbered and lettered circles by shifting between the two sets (part B) as quickly as possible, and is very sensitive to cerebral dysfunction. Part A of the test measures psychomotor speed. The results of part B reflect the ability to shift strategy and assess executive function and visuospatial working memory [18]. Time is recorded in seconds.

The Colour-Word Stroop Interference test (CWST).The first part of the test (part A)- Reading Colour Names in black (RNCb), measures verbal abilities and attention. The subject is asked to read as quickly as possible words (colour names) printed with black ink on a white card. The second part (part B): Naming the Colour of Word – different (NCWd) – measures verbal working memory and executive functions. The subject is asked to name the colour of each printed word. The colour of the printed word is different from the colour described by the word [12]. Scoring is based on time (seconds).

Verbal fluency tests. Phonologic verbal fluency was studied by asking subjects to generate as many words as possible that begin with each of the letters F, A and S, in consecutive 1-min time periods (FAS Test, from the Controlled Oral Word Association Test) [19]. Semantic verbal fluency was measured with the Category Instant Generation Test, by naming as many items as possible in a given category (animals, vegetables and fruits) within the same time limit. Scores were the sum of all acceptable words produced in the three trials. The Polish version of the FAS test was used. This test was used for the assessment of verbal fluency, which is also a sensitive measure of executive functions, as it requires the subject to generate his/her own strategy.

2.2.2. Cognitive tests: Selected tests from the Cambridge automated neuropsychological test battery

Rapid Visual Information Processing (RVP) - a test of visual sustained attention, which is sensitive to dysfunction in the parietal and frontal lobe areas of the brain and is also a sensitive measure of general performance. RVP A' is the signal detection measure of target sensitivity regardless of error tendency (range 0.00 to 1.00; bad to good). This metric is a measure of how good the subject is at detecting target sequences. RVP Mean latency measures the mean time taken to respond and is reported in milliseconds. Response latency in the RVP task is a good indicator of sustained attention function [20].

Stockings of Cambridge (SOC) is a visuospatial planning test based on the Tower of London task [21]. This is a spatial planning test which gives a measure of frontal lobe function. The subject is shown two displays containing three coloured balls. The displays are presented in such a way that they can easily be perceived as stacks of coloured balls held in stockings or socks suspended from a beam. This arrangement makes the 3-D concepts involved apparent to the subject, and fits with the verbal instructions. The subject must use the balls in the lower display to copy the pattern shown in the upper display. The balls may be moved one at a time by touching the required ball, then touching the position to which it should be moved. The time taken to complete the pattern and the number of moves required are taken as measures of the subject’s planning ability.

Spatial Span (SSP) - a visuospatial analogue of the Digit Span test assessing working memory capacity. White squares are shown, some of which briefly change colour in a variable sequence. The subject must then touch the boxes which changed colours in the same order that they were displayed by the computer (for clinical mode) or in the reverse order (for reverse mode). The number of boxes increases from 2 at the start of the test to 9 at the end, and the sequence and colour are varied through the test. After an incorrect attempt at choosing the boxes in sequence, the next trial remains at the same difficulty level. The Spatial Span is calculated at the highest level at which the subject successfully remembers at least one sequence of boxes.

Spatial Working Memory (SWM) - is a test of the subject’s ability to retain spatial information and to manipulate remembered items in the working memory, which measures the working memory for spatial stimuli and requires the subject to use mnemonic information to work towards a goal. Subjects are required to search through boxes that appear on the screen with the aim of finding the ‘blue tokens’ hidden inside. The key instruction is that once a token had been taken out of a box, that box would not be used again to hide a token. After two practice trials with two boxes, there were four test trials with each of two, three, four, six and eight boxes. Returning to an ‘empty’ box already opened and a token removed on a previous search constituted a ‘forgetting’ or ‘Between Search’ error (BSE). A Strategy score was calculated from subject's performance on the six and eight box levels, to reflect how often a searching sequence was initiated from the same box during a given trial. Higher Strategy scores represent lower use of strategy (i.e. many sequences beginning with a different box in a given trial), and lower scores represent efficient use of strategy (i.e. many sequences starting with the same box in a given trial). Statistical analyses

Statistical analyses were carried out with Statistica version 10.0 for Windows. To evaluate normality of distribution of the variables, the Shapiro–Wilk test was applied. As most of the investigated variables were not normally distributed, non-parametric tests were employed. Between-group differences in the demographic characteristics and neuropsychological tests were assessed by the Mann–Whitney test (two-groups comparisons) and Kruskal-Wallis ANOVA (multiple comparisons). All the results were expressed as the mean and standard deviation (S.D.). Statistical significance was set at p<0.05 for all analyses.


3. Results

Demographic characteristics are presented in table 1.

Bipolar patientsn=60 ERn=13 nonERn=47 Controlsn=84
Age (years) 52.6
Gender - Male: Female* 25: 35 7:6 18:29 25:59
Education (years) 13.7
Duration of illness 22.2
Duration of prophylactic lithium treatment 12.7
No. of recurrences 13.3
Intensity of depressive symptoms (HDRS) 2.6
(1.5) 1,2,3
Intensity of manic symptoms (YMRS) 0.6

Table 1.

Demographic and clinical characteristic of euthymic bipolar patients and healthy controls. ER - Excellent lithium responders; nonER- non – excellent responders; HAMD - Hamilton Depression Rating Scale; YMRS - Young Mania Rating Scale (values are expressed as mean, standard deviation is shown in brackets).

* chi-square test

1 – p<0.01 Mann-Whitney test, difference between bipolar patients and controls

2 – p<0.05 ANOVA difference between ER and controls

3 – p<0.01 ANOVA difference between nonER and controls

No differences in age, gender distribution as well as education level between bipolar patients and healthy controls were detected. No difference between excellent responders (ER) and non-excellent responders (nonER) were detected either. Bipolar patients were euthymic but scored significantly worse on Hamilton’s depression scale. Both ER and nonER had higher depression sores than the controls. In the bipolar group, 35 patients were treated with lithium as monotherapy, 13 – lithium in combination with carbamazepine, 4 – lithium+valproate, 8 – lithium+ atypical neuroleptic.

3.1. Assessment of attention, working memory and executive functions

To evaluate working memory planning and executive functions SSP, SWM, SOC from CANTAB Battery and the so-called “paper and pencil test”: fluency tests (semantic and phonemic), CWST part B, TMT A and B, were used. To asses sustained attention RVP (CANTAB), and part A from CWST were employed. In table 2 the results of the neuropsychological evaluation of bipolar patients treated with lithium and healthy controls are presented. The bipolar group consists of two subgroups: excellent lithium responders and the remaining patients (non- excellent lithium responders).

Subjects with bipolar disorder scored significantly worse than controls on the tests assessing working memory, executive functioning and planning. The longest sequence successfully recalled (SSP Span length) was significantly shorter in the patients group than the controls. SSP total error number was higher in the BD group than in the controls, but the difference was not statistically significant. On the Spatial Working Memory (SWM) test results are presented in two measures: strategy and between errors. Patient scored worse on both of them. On the SOC results were displayed as three dimensions: SOC Mean initial thinking time (5 moves) giving an indication of the time taken to plan the problem solution, SOC Mean subsequent thinking time (5 moves) as well as SOC Problems solved in a minimum number of moves recording the number of occasions upon which the subject has successfully completed a test problem in the minimum possible number of moves. Bipolar patients had significantly worse results in both initial and subsequent thinking times. The controls performed better on fluency tests (verbal and phonemic), and TMT both parts. On the CWST B measuring verbal working memory and executive functions, bipolar patients had significantly worse results than the control subjects. On the sustained attention tests patients also scored significantly worse. Results of RVP A' - the signal detection (a measure of how good the subject is at detecting target sequences) as well RVP Mean latency (a measure of the mean time taken to respond) were significant worse in the patients groups. After dividing lithium-treated patients into ELRs and non-ELRs the differences in cognitive functions between subgroups were observed. The results of excellent lithium responders were similar to those of healthy controls, whereas non-ELRs scored significantly worse on SSP Span length, SWM between errors and strategy, SOC initial thinking time, as well as sustained attention test. The only measure in which ELR scored worse than the controls was RVP mean latency. The results of ELRs were better than the scores of the controls on SSP span length and SOC problems solved in a minimum number of moves, but the difference did not reach statistical significance.

Bipolar patients ER nonER Controls
Working memory and planning, executive functions
SSP Span length 5.0
(1.2) 1,4
SWM Between errors 46.8
(18.7) 2,4
SWM Strategy 37.3
(4.8) 1,4
SOC Mean initial thinking time (5 moves) 11376.6
(5823.2) 2,4
SOC Mean subsequent thinking time (5 moves) 3649.0
(2955.0) 2
SOC Problems solved in a minimum number of moves 7.6
Semantic fluency (No of words) 40,8(9.0) 44,6(8.9) 39,7(10.0) 47,6(10,0)2
Phonemic fluency (No of words) 28,5(8.8) 33,3(9.3) 27,2(12.9) 35,6(12.9)2
CWST B (time [sec]) 78,7(26.3) 38,2(17.5) 46.0(10.9) 62,9(20,3)2
TMT A (time [sec]) 44,3(17.3) 89,2(39.0) 119,7(42.7) 36,1(10,9)2
TMT B (time [sec]) 113,2(46.80 65,5(19.4) 82,9(20.3) 81,3(42,7)2
Sustained attention
RVP A' 0.83
(0.05) 2,4
RVP Mean latency 604.7
(124.8) 2,3,4
RVP B'' 0.89
CWST A (time [sec]) 28,2(5.8) 26,8(5.1) 28,6(9.4) 28,4(9.4)

Table 2.

Neuropsychological evaluation of bipolar patients and healthy controls treated with lithium and healthy controls (values are expressed as mean and standard deviation in brackets). Table presents results of CANTAB tests and paper-and-pencil tests results.

1 –difference between BD and controls p< 0.05 Mann-Whitney test

2 - difference between BD and controls p<0.01 Mann-Whitney test

3 - difference between ER and controls (p<0.05) ANOVA

4 – difference between non-ER and controls (p<0.05) ANOVA


4. Discussion

4.1. Cognitive functions in bipolar patients

Not so long ago it was claimed that bipolar disorder is episodic, and the patient fully recovers between episodes, with no signs of affective, cognitive or psychosocial symptoms [2]. But patients in remission seem to be both affectively disturbed and cognitively impaired which may be a contributory factor to poor psychosocial outcome [2, 22-25]. During the last decade the results of numerous neurocognitive and neuroimaging studies in BD have been reported. They have revealed various dysfunctions in bipolar disorder present during affective episodes and have demonstrated that many neurocognitive deficits persist into periods of clinical remission or euthymia [16, 26]. Patients during affective episodes show significantly lower performance on several measures (tests) of attention, executive function, learning and verbal memory, and psychomotor speed [27-29].

Disturbances of executive functions, verbal and visual memory dysfunctions have been observed in depressive bipolar patients [23, 29-31]. Results of studies in manic patients are less consistent - although impairments in executive functions have been reported [23, 30-35]. Sweeney et al. [30] reported worse results of manic compared to depressive bipolar patients. Manic, but not depressed, patients made suboptimal decisions in Murphy’s [35] computerized decision-making task.

Results of neuroimaging scans show structural and functional brain abnormalities in mood disorders in such regions as: basal ganglia frontal lobes, the locus caeruleus, subcortical white matters, hipoccampus, amygdala, temporal lobes, as well as subtle structural deficits in the dorsal raphe [28, 36]. Cognitive dysfunctions were observed in affective acute bipolar patients (attention deficits, flexibility deficits, verbal fluency impairment, memory disturbances) [13, 31, 32, 35] have been reported also during periods of remission [37, 38], independently from residual affective symptoms [1, 16]. Sustained cognitive deficits could be a marker of disease or bipolar traits, it could be a prognostic factor as well [37]. Still, there is ambiguity about those issues [23, 39]. Research results are inconsistent [39], in small groups, diagnosis of bipolar is not precise, and information about treatment is not provided [23].

Recent reports have suggested the presence of persistent cognitive impairments in patients diagnosed with BD even after prolonged euthymic phases [16, 26, 40-48]. Review by Torres et al. [4] revealed widespread cognitive deficits in tests assessing attention, speed of information processing, memory and executive dysfunctions in remitted bipolars versus controls. There was no difference in premorbid intelligence and vocabulary. Some dysfunctions in remitted patients [49] are similar to those observed in patients in acute phase. Cognitive deficits are regarded by several authors as trait-markers or their background (genetic, developmental or associated with illness progression) remains to be evaluated [4]. The studies in euthymic patients are to answer questions concerning the state-dependent (reflecting mood changes) and stable character of cognitive deficits [2, 26, 40, 41, 50, 51].

Disturbances of executive functions, working memory and planning. The results of our study confirmed the reports on disturbances of executive functions in remitted bipolar patients [42-48; 52-54]. Several authors do not show executive dysfunctions [55, 56] or show mild degree dysfunctions [4]. These discrepancies probably result from various definitions of executive function, which lead to the use of different tests and methods as well as problems with clear explanation of the nature of cognitive dysfunction(s). Disturbances of cognitive flexibility and inhibitory control were the most important findings, auditory memory and verbal fluency were more impaired. Intellectual functioning was intact. A recent review of the literature [57] shows deficits in working memory and some aspects of executive functions (inhibitory control).

Larson [58] et al. evaluated two specific aspects of executive functioning: inhibitory control, and spatial delayed working memory. Manic and euthymic patient groups performed similarly in the spatial delayed working memory test. On the inhibitory test manic and euthymic patients committed significantly more perseverative errors than healthy participants. These results indicated that patients had relatively normal working memory abilities, but had a deficit in behavioral self-regulation, which was evident across mood states. In our bipolar remitted group spatial working memory (SWM) was disturbed compared to the control group, and subjects performed worse when it came to updating the working memory continually but strategy planning was less disturbed.

Goswami et al. [59] have measured neurocognitive functions in bipolar disorder and tried to find links to residual mood symptoms, soft neurological signs and psychosocial impairment. They tested attention, memory and executive function in euthymic patients with bipolar disorder and controls. Psychosocial functioning, soft neurological signs and residual mood symptoms were assessed. Tests results on executive function and verbal memory (but not attention) were significantly poorer in bipolar patients. Residual (sub-syndromal) mood symptoms were connected with small cognitive effects, predominantly on verbal memory. Some patients showed a marked social disability which correlated strongly with soft neurological signs but weakly with executive dysfunction, which was linked to the number of episodes. Cognitive dysfunction, social dysfunction and soft signs may represent trait deficits of bipolar illness. Both in the present study and in other authors’ results remitted bipolar patients have verbal and nonverbal memory disturbances [4] compared to healthy controls. Those results are consistent through various data [49], a wide spectrum of executive dysfunctions, memory and attention was detected in remitted bipolars [25]. The results of our study are consistent with those of Sole et al. [60] who reported that bipolar patients showed a significantly lower performance on several measures of attention, learning and verbal memory, and executive function compared with healthy controls. Worse performance on TMT is especially important in light of the finding of Sole et al. [60] that the one measure related to executive function (Trail Making Test, part B) was the variable that best predicted psychosocial functioning of bipolar patients. In a two year follow up study in euthymic bipolar patients on lithium executive function and processing speed were affected, and such deficits were maintained over time. Those results show that executive dysfunction is the main long-term neuropsychological deficit of bipolar disorder [61]. After controlling for the effect of subsyndromal depressive symptoms [62] impairment of verbal memory and executive dysfunctions were noticed and this cognitive impairment seems to be related to a worse clinical course and poor functional outcome. Executive dysfunctions are described as a central bipolar trait deficit and due to them bipolars’ psychosocial problems are observed [63].

Attention deficits. The results of our study point to the deficits in attention tests. Patients scored worse on sustained attention measurement WCST part B and on RVP test from CANTAB battery. Euthymic bipolar patients have been reported to show persistent deficits in sustained attention tests [53]. Most research shows sustained attention deficits [41, 46], some tests did not show such disturbances [4]. Burdick [64] has not detected a direct relationship between attention deficits and depressive symptoms. Sustained attention deficits apparent during the euthymic period of bipolar disorder cannot be explained in terms of working memory impairment and represent a reduced inherent capacity rather than a changed response bias [16, 42, 44, 45, 53, 65, 66]. Sustained attention deficits are claimed to be a core deficit for bipolar disorder, but those deficits are not dependent on executive dysfunctions, including working memory. Attention deficits and information-processing speed are related to memory processing or other cognitive processes [2, 39, 47, 48]. Furthermore, the data support the view that deficits in verbal memory may be related to genetic factors. [65].

Memory deficits as result of hipoccampal and medial temporal lobe dysfunctions could be a key cognitive problem in bipolar patients [67]. Malhi et al. [68] conducted a review of the literature to compare and contrast the neuropsychological profile of the 3 phases of bipolar disorder to identify potential state and trait deficits. They initially identified more than 100 articles and then excluded reviews and papers in which neuropsychological tests were not administered directly. This left 27 papers, which they further examined and the findings of which they tabulated and discussed. Cognitive and executive functioning deficits were found, including set-shifting, verbal fluency, planning, attention, and memory. In their opinion, those neuropsychological deficits found in bipolar depression, mania or hypomania, and euthymia provide important insights into the pathophysiology of bipolar disorder and may, in future studies, form the basis of clinically meaningful subtypes of bipolar disorder [68]. Deficits in sustaining attention may also help explain the difficulties in psychological and occupational functioning in bipolar disorder patients during remission.

4.2. Factors associated with cognitive deficits

Cognitive impairments result not only from affective disturbances (manic, depression phases) - they are also detectable during the phase free of affective symptoms (remission) Factors associated with cognitive dysfunction in bipolars might be the number of episodes [1, 38, 54], mainly the number of manic episodes [16, 41, 52, 54, 69, 70], chronicity [53, 54], residual affective symptoms, especially depressive ones [27, 38]. Clinical factors associated with cognitive impairment in bipolar patients are medicines such as mood stabilizers, antidepressants and neuroleptics. Drugs used in the treatment for somatic diseases might also influence the cognitive functioning of bipolar patients.The secondary cognitive deficits caused by treatment of bipolar disorder (lithium, antiepileptics, antidepressants, antipsychotics) are similar to the cognitive deficits associated with the disease [71]. Differentiation between cognitive dysfunctions related to the illness and those related to its treatment is difficult. Four studies showed that lithium had a negative effect on memory and speed of information processing, often without subjective complaints or awareness of mental slowness [72, 73], lithium did not cause memory impairment or a change in self-assessment of memory functions [74]. In Engelsmann et al. observation survey mean memory test scores remained remarkably stable over the entire 6-year lithium therapy [75]. A comparison between two groups on lithium therapy: a long- and shorter term group (with means of 12.9 and 5.2 years, respectively) showed no significant differences between these groups on any of the memory tests [31]. Younger bipolars (below 55 yrs) had received lithium therapy for 1-5 years and showed no abnormalities on the Halstead-Reitan Neuropsychological Battery, so lithium therapy was not connected with cognitive impairment [76].

Cognitive function in log-term lithium-treated outpatients were investigated by Lund et al. [77] who tested memory, attention, speed, loss of effort, level of processing, productivity [77]. Results were within normal limits. But further analyses revealed that the performance of the lithium-treated patients indicated a relative lowering of the level of memory and perceptual processing when compared to the level of attention and productivity. Those results support opinion about lithium –influenced worsening in information processing. The effects of blind lithium discontinuation and resumption on measures of cognition, creativity, and fine motor performance in 46 lithium-maintained euthymic out-patients were investigated [72]. Scores on memory measures, tests of tapping speed, and associative productivity all improved significantly during the time off of lithium. The authors analyzed influence of six possible intervening variables: age, sex, lithium concentration in plasma, thyroid function, duration of lithium maintenance, and depressive symptoms. Further analysis suggested that lithium has a greater neuropsychological effect in younger, less-depressed patients having higher plasma lithium concentrations in plasma [72].

In our study lithium-treated patients as a group had poorer results on several tests measures compared to healthy controls, namely SSP span length, SWM between errors, SWM strategy, RVP A, RVP mean latency, and SOC mean initial thinking time as well as on TMT and Stroop test part B. The results of excellent lithium responders did not differ from those of healthy controls (except for one measure in RVP). These might support statement that lithium treatment is associated with a preservation of cognitive functions in ER group. According to literature review [78] neurostructural changes in BD would be hypothetically influenced by the neuroprotective/neurotrophic properties of lithium. These findings are interesting because the pathophysiology of BD involves structural and functional changes in cortical and limbic networks implicated in the regulation of mood and cognition. Reports on the impact of anticonvulsants on cognitive functions in bipolar patients are scarce. Some authors reported that plasma levels of anticonvulsants influence cognitive tests results and carbamazepine or valproinians may be responsible for attention deficits [79, 80]. Neuroleptics have been found to worsen psychomotor function and sustained attention, but higher cognitive functions are relatively unaffected [81]. Zubieta et al. [41] have found negative correlations between Wisconsin Card Sorting Test (WCST) performance and duration of neuroleptics exposition. The use of neuroleptics [82] as well as illness duration and family history were predictive factors for intelligence and memory in bipolar patients. Numerous authors believe that neuroleptics do not influence cognitive functions in bipolars. Cognitive deficits are related probably to anticholinergics effects of drugs [31]. New neuroleptics (atypical) have positive impact on cognitive functions of schizophrenic patients [83], and probably new neuroleptics improve cognitive function especially in longtime treatment for manic patients [31].

Data on antidepressants are also inconsistent. Literature review shows that antidepresants do not cause cognitive dysfunctions [84]. According to literature review by Knegtering et al. [85] amitriptyline, mianserin and trazodone impair attention and ability to concentrate in elderly, antidepressants with anticholinergic properties (nortriptyline, maprotiline, amitriptyline) might impair working memory. Higher plasma concentrations of nortriptyline correlate with greater cognitive impairment. Tests results about selective serotonin (5-hydroxytryptamine) reuptake inhibitors on cognitive performance in the elderly indicate no detrimental effect. Martinez et al. pointed out that mood stabilizers with antidepressant properties might influence cognitive function and social functioning [31]. Optimal treatment preferring second generation antipsychotics and avoiding drugs with anticholinergic effect, is essential. In Mencier and colleagues opinion prevention of iatrogenic effects of drugs should be now the main therapeutic intervention [71]. Treatment with atypical antipsychotics has been associated with improvement in cognitive tests in patients with schizophrenia, and the little data available in patients with bipolar disorder suggest the potential for similar benefits. MacQueen and Young [86] pointed to the need of further studies to determine if current treatments for bipolar disorder can prevent, delay, or even improve cognitive dysfunctions [86]. Bipolar patient have been treated for years with combination of mood stabilizers, antidepressants and antipsychotics and it is difficult to assess impact of such a combination on various cognitive functions. [28, 34]. Impaired executive functions in bipolars shown in tests might be the feature of bipolar disorder regardless the effects of medication [87]. The contributions of bipolar disorder trait –state cognitive impairment and medications is very complicated to distinguish as well as control [78]. Clinicians treating BD patients should take it into account in prescribing medications for long-term prophylaxis. Medication-related adverse cognitive effects should be taken into consideration. In order to reduce cognitive dysfunction, or at least avoid cognitive deterioration clinicians should use drugs with a favourable or neutral cognitive profile [78]. Cognitive outcome in patients with affective disorders appears to be associated with the number of affective episodes. In the study designed as a controlled cohort study [38] 118 unipolar patients, 28 bipolar patients and 58 controls were included and the analysis results was adjusted to the level of education and subclinical depressive and anxiety symptoms. Patients with recurrent episodes were significantly more impaired than patients with a single episode and more impaired than controls. Some research on bipolar showed negative correlations between number of depressive episodes and executive functions [16, 41, 42]. Verbal learning was correlated with number of depressive episodes [63] or not [42, 52]. Number of manic episodes was connected with worse results in verbal tests and worsening in executive functions tests [16, 41, 52, 54, 62, 63] and visual memory [88]. Systematic literature review by Robinson and Ferrier [25] showed relationship between cognitive dysfunction in bipolar disorder and worse prior course of illness, particularly the number of manic episodes, hospitalizations and length of illness. In their opinion cognitive impairment may be a trait vulnerability factor for bipolar disorder that is present before illness onset and worsens as the illness progresses. Residual affective symptoms might influence cognitive tests results [2, 16, 56, 89]. It is worth to underline that in previous studies usually euthymic patients meant patients free of affective symptoms who did not fulfilled criteria for affective episode. On the other hand 30% of Scott’s [90] group of remitted bipolar had patients Beck’s score was more than 10 points. In cognitive functions assessment in BD we should consider such factors as pharmacological treatment, course of illness, residual symptoms [2, 16], structural lesions of a neurodegenerative origin [91, 92], functional changes that are most likely genetic in origin [91-93]. There is a close relationship between cognitive impairment and poor treatment adherence, but the causal inferences of these findings are uncertain [94]. Poor treatment adherence may worsen the course of bipolar disorder and so indirectly worsen cognitive performance, or cognitive impairment may contribute to poor treatment adherence and reflect more severe illness.


5. Conclusion and future research

Data concerning cognitive functions in BD are still limited and inconsistent so that further research is necessary. It is worth to underline the growing evidence suggests that the presence of cognitive dysfunction in bipolar affective disorder is a core and enduring deficit of the illness. Impairment in the attention or executive control of action represents an important target for future research. Many clinicians have strongly indicated worse psychosocial functioning of bipolar patients [41, 95], which may be caused by cognitive impairment as neurocognitive deficits could result in psychological and social deficits. Evidence from neuroimaging, molecular genetic, pharmacological and animal studies related to the pathophysiology of bipolar disorder may provide clinicians with new treatment strategies. Neurocognitive impairment in bipolar disorder should be considered a potential therapeutic target, which means that research should focus on new drugs and psychological interventions, including neurocognitive rehabilitation to improve cognitive functions and the functional outcome of bipolar patients [96]. The Cognitive Remediation is defined as a behavioural training based intervention aimed at the improvement of cognitive processes (attention, memory, executive function, social cognition or metacognition) with the goal of durability and generalization [97]. Several cognitive remediation programmes (CR) for patients with schizophrenia have already been developed. The potential benefits of CR in affective disorders may even exceed those of schizophrenia and such approaches hold significant promise for individuals with bipolar disorder [98].


  1. 1. FerrierI. Nand J. MThompsonCognitive impairment in bipolar affective disorder: implications for the bipolar diathesis. Br J Psychiatry, 2002293295
  2. 2. FerrierI. Net alNeuropsychological function in euthymic patients with bipolar disorder, in British Journal of Psychiatry. 1999246251
  3. 3. ScottJPsychotherapy for bipolar disorder. Br J Psychiatry, 1995581588
  4. 4. TorresI. JV. GBoudreauand L. NYathamNeuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl, 20071726
  5. 5. StefanopoulouEet alCognitive functioning in patients with affective disorders and schizophrenia: a meta-analysis. Int Rev Psychiatry, 2009336356
  6. 6. LatalovaKet alCognitive impairment in bipolar disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 20111926
  7. 7. FirstMet alStructured Clinical Interview for DSM-IV Axis I Disorders, Research Version. 1997New York: Biometrics Research.
  8. 8. HamiltonMA rating scale for depression. J Neurol Neurosurg Psychiatry, 19605662
  9. 9. YoungRet alA rating scale for mania: Reliability, validity, and sensitivity, in British Journal of Psychiatry. 1978429435
  10. 10. GrofPExcellent lithium responders: people whose lives have been changed by lithium prophylaxis, in Lithium: 50 Years of Psychopharmacology, New Perspectives in Biomedical and Clinical Research, N.J. Birch, V.S. Gallicchio, and R.W. Becker, Editors. 1999Weidner Publishing Group: Cheshire, Connecticut 3651
  11. 11. ReitanR. MThe relation of the trail making test to organic brain damage. J Consult Psychol, 1955393394
  12. 12. StroopJ. RStudies of interference in serial verbal reaction. J Exp Psychol, 1935643662
  13. 13. BorkowskaAand J. KRybakowskiNeuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar. Bipolar Disord, 20018894
  14. 14. ElliottRet alNeuropsychological impairments in unipolar depression: the influence of perceived failure on subsequent performance. Psychol Med, 1996975989
  15. 15. PurcellRet alNeuropsychological function in young patients with unipolar major depression. Psychol Med, 199712771285
  16. 16. ClarkLS. DIversenand G. MGoodwinSustained attention deficit in bipolar disorder. Br J Psychiatry, 2002313319
  17. 17. OwenA. Met alPlanning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci, 1996353364
  18. 18. ReitanR. MValidity of theTrail MakingTest as an indicator of organic brain damage. Percept Mot Skills, 1958
  19. 19. BorkowskiJand ABentonWord fluency and brain damage. Neuropsychologia, 1967135140
  20. 20. SahakianBet alThe effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type. Br J Psychiatry, 1989797800
  21. 21. ShalliceTSpecific impairments of planning. Philos Trans R Soc Lond B Biol Sci, 1982199209
  22. 22. GoodwinF. Kand K. RJamisonManic Depressive Illness 1990Oxford University Press: Oxford.
  23. 23. MalhiG. Set alNeuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord, 2007114125
  24. 24. BlumbergH. Pet alA functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry, 2003601609
  25. 25. RobinsonL. Jand I. NFerrierEvolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord, 2006103116
  26. 26. Martinez-aranAet alCognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord, 2004a224232
  27. 27. Martinez-aranAet alCognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom, 2000218
  28. 28. BeardenC. EK. MHoffmanand T. DCannonThe neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord, 2001106150discussion 151-3.
  29. 29. QuraishiSand SFrangouNeuropsychology of bipolar disorder: a review. J Affect Disord, 2002209226
  30. 30. SweeneyJ. AJ. AKmiecand D. JKupferNeuropsychologic impairments in bipolar and unipolar mood disorders on the CANTAB neurocognitive battery. Biol Psychiatry, 2000674684
  31. 31. Martinez-aranAet alCognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry, 2004262270
  32. 32. ClarkLS. DIversenand G. MGoodwinA neuropsychological investigation of prefrontal cortex involvement in acute mania. Am J Psychiatry, 200116051611
  33. 33. GoldbergT. Eet alContrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry, 199313551362
  34. 34. MurphyF. Cand B. JSahakianNeuropsychology of bipolar disorder. Br J Psychiatry Suppl, 2001s120s127
  35. 35. MurphyF. Cet alDecision-making cognition in mania and depression. Psychol Med, 2001679693
  36. 36. BaumannBand BBogertsNeuroanatomical studies on bipolar disorder. Br J Psychiatry Suppl, 2001s142s147
  37. 37. MckayA. Pet alNeuropsychological function in manic-depressive psychosis. Evidence for persistent deficits in patients with chronic, severe illness. Br J Psychiatry, 19955157
  38. 38. KessingL. VCognitive impairment in the euthymic phase of affective disorder. Psychol Med, 199810271038
  39. 39. OlleyAet alWhen euthymia is just not good enough: the neuropsychology of bipolar disorder. J Nerv Ment Dis, 2005a323330
  40. 40. El-BadriS. Met alElectrophysiological and cognitive function in young euthymic patients with bipolar affective disorder. Bipolar Disord, 20017987
  41. 41. ZubietaJ. Ket alCognitive function in euthymic bipolar I disorder. Psychiatry Res, 2001920
  42. 42. ThompsonJ. Met alNeurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry, 20053240
  43. 43. FleckD. EP. KShearand S. MStrakowskiProcessing efficiency and directed forgetting in bipolar disorder. J Int Neuropsychol Soc, 2005871880
  44. 44. ClarkLet alSustained attention-deficit confirmed in euthymic bipolar disorder but not in first-degree relatives of bipolar patients or euthymic unipolar depression. Biol Psychiatry, 2005a183187
  45. 45. Wilder-willisK. Eet alPersistent attentional dysfunction in remitted bipolar disorder. Bipolar Disord, 20015862
  46. 46. SwannA. Cet alImpulsivity and phase of illness in bipolar disorder. J Affect Disord, 2003105111
  47. 47. GruberS. AJRogowskaand D. AYurgelun-toddDecreased activation of the anterior cingulate in bipolar patients: an fMRI study. J Affect Disord, 2004191201
  48. 48. MonksP. Jet alA functional MRI study of working memory task in euthymic bipolar disorder: evidence for task-specific dysfunction. Bipolar Disord, 2004550564
  49. 49. PlacaisBet alContinuum electrodynamics of type-II superconductors in the mixed state: The dc and ac response. Phys Rev B Condens Matter, 19961308313096
  50. 50. DixonTet alEffect of symptoms on executive function in bipolar illness. Psychol Med, 2004811821
  51. 51. KrabbendamLet alCognitive dysfunctions and white matter lesions in patients with bipolar disorder in remission. Acta Psychiatr Scand, 2000274280
  52. 52. CavanaghJ. Tet alCase-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry, 2002320326
  53. 53. HarmerC. Jet alSustained attention deficit in bipolar disorder is not a working memory impairment in disguise. Neuropsychologia, 200215861590
  54. 54. Van GorpW. Get alCognitive impairment in euthymic bipolar patients with and without prior alcohol dependence. A preliminary study. Arch Gen Psychiatry, 19984146
  55. 55. RossiAet alCognitive function in euthymic bipolar patients, stabilized schizophrenic patients, and healthy controls. J Psychiatr Res, 2000333339
  56. 56. RubinszteinJ. Set alCognitive impairment in remission in bipolar affective disorder. Psychol Med, 200010251036
  57. 57. SoleBet alAre bipolar II patients cognitively impaired? A systematic review. Psychol Med, 201117911803
  58. 58. LarsonE. Ret alWorking memory and inhibitory control among manic and euthymic patients with bipolar disorder. J Int Neuropsychol Soc, 2005163172
  59. 59. GoswamiUet alNeuropsychological dysfunction, soft neurological signs and social disability in euthymic patients with bipolar disorder. Br J Psychiatry, 2006366373
  60. 60. SoleBet alNeurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand, 2012309317
  61. 61. MurMet alLong-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. J Clin Psychiatry, 2008712719
  62. 62. Martinez-aranAet alCognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord, 2004224232
  63. 63. DeckersbachTet alEpisodic memory impairment in bipolar disorder and obsessive-compulsive disorder: the role of memory strategies. Bipolar Disord, 2004233244
  64. 64. BurdickK. Eet alAttention and psychomotor functioning in bipolar depression. Psychiatry Res, 2009192200
  65. 65. KieseppaTet alMemory and verbal learning functions in twins with bipolar-I disorder, and the role of information-processing speed. Psychol Med, 2005205215
  66. 66. FleckD. EP. KShearand S. MStrakowskiProcessing efficiency and sustained attention in bipolar disorder. J Int Neuropsychol Soc, 20054957
  67. 67. SavitzJMSolmsand RRamesarNeuropsychological dysfunction in bipolar affective disorder: a critical opinion. Bipolar Disord, 2005216235
  68. 68. MalhiG. Set alBipolar disorder: it’s all in your mind? The neuropsychological profile of a biological disorder. Can J Psychiatry, 2004813819
  69. 69. AltshulerL. LBipolar disorder: are repeated episodes associated with neuroanatomic and cognitive changes? Biol Psychiatry, 1993563565
  70. 70. ChristensenM. VK. OKyvikand L. VKessingCognitive function in unaffected twins discordant for affective disorder. Psychol Med, 200611191129
  71. 71. MenecierPet alBipolar disorders and dementia: fortuitous association or filiation? A case-report and review of the literature.]. Psychol Neuropsychiatr Vieil, 20072334
  72. 72. KocsisJ. Het alNeuropsychologic effects of lithium discontinuation. J Clin Psychopharmacol, 1993268275
  73. 73. HonigAet alLithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. Int Clin Psychopharmacol, 1999167171
  74. 74. SquireL. Ret alEffects of lithium carbonate on memory and other cognitive functions. Am J Psychiatry, 198010421046
  75. 75. EngelsmannFet alLithium and memory: a long-term follow-up study. J Clin Psychopharmacol, 1988207212
  76. 76. FriedmanM. JC. MCulverand R. BFerrellOn the safety of long-term treatment with lithium. Am J Psychiatry, 197711231126
  77. 77. LundYMNissenand O. JRafaelsenLong-term lithium treatment and psychological functions. Acta Psychiatr Scand, 1982233244
  78. 78. Balanza-martinezVet alNeurocognition in bipolar disorders--a closer look at comorbidities and medications. Eur J Pharmacol, 20108796
  79. 79. DevinskyOCognitive and behavioral effects of antiepileptic drugs. Epilepsia, 1995Suppl 2: S46S65
  80. 80. ThompsonP. Jand M. RTrimbleAnticonvulsant drugs and cognitive functions. Epilepsia, 1982531544
  81. 81. KingD. JPsychomotor impairment and cognitive disturbances induced by neuroleptics. Acta Psychiatr Scand Suppl, 19945358
  82. 82. DonaldsonSet alThe Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. J Clin Psychiatry, 20038693
  83. 83. BorkowskaAet alRisperidone treatment of schizophrenia: improvement in psychopathology and neuropsychological tests. Neuropsychobiology, 20028589
  84. 84. ThompsonP. JAntidepressants and memory: a review. Hum Psychopharmacol 19917990
  85. 85. KnegteringHMEijckand AHuijsmanEffects of antidepressants on cognitive functioning of elderly patients. A review. Drugs Aging, 1994192199
  86. 86. MacqueenGand TYoungCognitive effects of atypical antipsychotics: focus on bipolar spectrum disorders. Bipolar Disord, 2003Suppl 2: 5361
  87. 87. MurMet alPersistent neuropsychological deficit in euthymic bipolar patients: executive function as a core deficit. J Clin Psychiatry, 200710781086
  88. 88. DeckersbachTet alCharacteristics of non-verbal memory impairment in bipolar disorder: the role of encoding strategies. Psychol Med, 2004823832
  89. 89. ClarkLand G. MGoodwinState- and trait-related deficits in sustained attention in bipolar disorder. Eur Arch Psychiatry Clin Neurosci, 20046168
  90. 90. ScottJet alCognitive vulnerability in patients with bipolar disorder. Psychol Med, 2000467472
  91. 91. AliS. Oet alRelationship between prior course of illness and neuroanatomic structures in bipolar disorder: a preliminary study. Neuropsychiatry Neuropsychol Behav Neurol, 2001227232
  92. 92. DenicoffK. Det alRelationship between prior course of illness and neuropsychological functioning in patients with bipolar disorder. J Affect Disord, 19996773
  93. 93. GlahnD. Cet alThe feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disord, 2004171182
  94. 94. Martinez-aranAet alTreatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry, 2009
  95. 95. Martinez-aranAet alExecutive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome. Psychother Psychosom, 20023946
  96. 96. GoodwinG. Met alCognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol, 2008787793
  97. 97. WykesTCognitive remediation therapy needs funding. Nature, 2010165166
  98. 98. AnayaCet alA systematic review of cognitive remediation for schizo-affective and affective disorders. J Affect Disord, 2012

Written By

Aleksandra Suwalska and Dorota Łojko

Submitted: May 18th, 2012 Published: January 23rd, 2013